154 related articles for article (PubMed ID: 28232048)
1. Tackling pancreatic cancer with metronomic chemotherapy.
Romiti A; Falcone R; Roberto M; Marchetti P
Cancer Lett; 2017 May; 394():88-95. PubMed ID: 28232048
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
[TBL] [Abstract][Full Text] [Related]
3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
4. Current achievements and future perspectives of metronomic chemotherapy.
Romiti A; Falcone R; Roberto M; Marchetti P
Invest New Drugs; 2017 Jun; 35(3):359-374. PubMed ID: 27909934
[TBL] [Abstract][Full Text] [Related]
5. Tumor endothelial cells as a potential target of metronomic chemotherapy.
Kim JY; Kim YM
Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
[TBL] [Abstract][Full Text] [Related]
6. Metronomic chemotherapy in metastatic colorectal cancer.
Woo IS; Jung YH
Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic targets for pancreatic cancer.
Tang SC; Chen YC
World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.
Chen X; Bui KC; Barat S; Thi Nguyen ML; Bozko P; Sipos B; Kalesse M; Malek NP; Plentz RR
Cancer Lett; 2017 Jul; 399():20-28. PubMed ID: 28408354
[TBL] [Abstract][Full Text] [Related]
9. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
11. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
14. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
15. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.
Onesti CE; Romiti A; Roberto M; Falcone R; Marchetti P
Expert Rev Anticancer Ther; 2015; 15(10):1183-98. PubMed ID: 26325474
[TBL] [Abstract][Full Text] [Related]
16. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
Levitt JM; Jian W; Lerner SP; Sonpavde G
Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
18. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
Roberto M; Romiti A; Onesti CE; D'Antonio C; Milano A; Falcone R; Barucca V; Palombi L; Righini R; Marchetti P
Anticancer Drugs; 2016 Feb; 27(2):106-11. PubMed ID: 26473528
[TBL] [Abstract][Full Text] [Related]
19. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
Loven D; Hasnis E; Bertolini F; Shaked Y
Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084
[TBL] [Abstract][Full Text] [Related]
20. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
